close
    why is elan share price rising

    0  Views: 766 Answers: 1 Posted: 12 years ago

    1 Answer

    a proprietary survey of multiple sclerosis specialists suggests the market position of Elan's MS drug Tysabri against Novartis AG's (NVS, NOVN.VX) Gilenya is secure.


    Top contributors in Uncategorized category

     
    ROMOS
    Answers: 18061 / Questions: 154
    Karma: 1101K
     
    Colleen
    Answers: 47270 / Questions: 115
    Karma: 953K
     
    country bumpkin
    Answers: 11322 / Questions: 160
    Karma: 838K
     
    Benthere
    Answers: 2392 / Questions: 30
    Karma: 760K
    > Top contributors chart
    452261
    questions
    719710
    answers
    754063
    users